Skip to content
Medical Health Aged Care

Vale John Daffey FPS

Pharmaceutical Society of Australia (PSA) < 1 mins read

The Pharmaceutical Society of Australia (PSA) is deeply saddened to hear of the passing of former National President John Daffey FPS.  

Mr Daffey served as PSA’s National President between 2000 and 2001, on top of his 15 years of service on PSA’s Victorian Branch from 1987 to 2002.   

PSA National President Dr Fei Sim FPS expressed her deepest condolences to Mr Daffey’s colleagues, family, friends and loved ones.   

“John made many valuable contributions to our profession, both as a community pharmacist and as a national leader,” Dr Sim said.   

“John is well known for his leadership and collegiality throughout negotiations for the 3rd Community Pharmacy Agreement, working collaboratively with the Pharmacy Guild of Australia to get the best outcomes for Australian pharmacists and patients.  

“His loss comes at a difficult time for pharmacists around Australia, and there has never been a more important time for our profession to unite in John’s spirit of solidarity.  

“On behalf of the pharmacy profession, my deepest condolences are with the Daffey family, their friends, and many colleagues in Victoria,” Dr Sim concluded. 

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: georgia.clarke@psa.org.au

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.